Business Editors & Health/Medical Writers
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec. 23, 2002
Coupon Program Makes Alavert(TM) Available at a Cost of $11
for a One-Month Supply
Blue Cross of California today announced the implementation of a program
Dr. Robert Seidman, Blue Cross' chief pharmacy officer, said the availability of the new OTC Alavert will help make controlling allergy symptoms more economical and convenient. "We have entered into a strategic partnership with Wyeth Consumer Healthcare, the marketer of Alavert, to offer discount coupons for this popular drug to our members."
Blue Cross is sending information about this program to all of its members who have received prescriptions for Claritin, Allegra, Zyrtec or Clarinex during the past six months. Included in this mailing are three Alavert coupons with a redemption value of $10 each towards the purchase of Alavert tablets in a convenient, quick-dissolving form that can be taken with or without water. Using these coupons will allow its members to purchase Alavert at a cost that is less than the average Blue Cross brand name drug co-payment.
Wyeth Consumer Healthcare's suggested retail price for a 48-count Alavert package is approximately $27, which equates to a cost of approximately 57 cents per tablet. With the coupon, the cost of Alavert will be 35 cents per tablet or about $11 for a one-month supply.
"Prescription costs are increasing at a rate that is not sustainable," said Seidman. "This is part of an ongoing effort to help protect the affordability of health benefits. This is good news for our members who now have a choice of safe, effective, affordable non-sedating antihistamines without a doctor's prescription or co-payments.
"Historically, the higher cost of prescription antihistamines and physician office visits have been paid, in part, by our members through their health insurance premiums," said Seidman. "The movement to OTC non-sedating antihistamines helps us mitigate the rise in health insurance premiums. It also helps us direct resources to life-essential medications developed by the pharmaceutical industry in other therapeutic classes."